- Home
- IGR vs GYRE Comparison
IGR vs GYRE Comparison
Compare IGR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- GYRE
- Stock Information
- Founded
- IGR 2004
- GYRE 2002
- Country
- IGR United States
- GYRE United States
- Employees
- IGR N/A
- GYRE N/A
- Industry
- IGR Finance Companies
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- GYRE Health Care
- Exchange
- IGR Nasdaq
- GYRE Nasdaq
- Market Cap
- IGR 752.8M
- GYRE 897.1M
- IPO Year
- IGR N/A
- GYRE N/A
- Fundamental
- Price
- IGR $4.92
- GYRE $7.27
- Analyst Decision
- IGR
- GYRE
- Analyst Count
- IGR 0
- GYRE 0
- Target Price
- IGR N/A
- GYRE N/A
- AVG Volume (30 Days)
- IGR 747.7K
- GYRE 81.2K
- Earning Date
- IGR 01-01-0001
- GYRE 08-12-2025
- Dividend Yield
- IGR 13.93%
- GYRE N/A
- EPS Growth
- IGR N/A
- GYRE N/A
- EPS
- IGR N/A
- GYRE 0.02
- Revenue
- IGR N/A
- GYRE $100,643,000.00
- Revenue This Year
- IGR N/A
- GYRE $21.04
- Revenue Next Year
- IGR N/A
- GYRE $89.64
- P/E Ratio
- IGR N/A
- GYRE $92.27
- Revenue Growth
- IGR N/A
- GYRE N/A
- 52 Week Low
- IGR $3.88
- GYRE $6.11
- 52 Week High
- IGR $5.70
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- IGR 35.64
- GYRE 44.07
- Support Level
- IGR $4.90
- GYRE $7.09
- Resistance Level
- IGR $5.07
- GYRE $7.89
- Average True Range (ATR)
- IGR 0.08
- GYRE 0.37
- MACD
- IGR -0.03
- GYRE 0.04
- Stochastic Oscillator
- IGR 11.84
- GYRE 24.39
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.